Literature DB >> 20720054

Reproducibility of 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET tumor volume measurements.

Mathieu Hatt1, Catherine Cheze-Le Rest, Eric O Aboagye, Laura M Kenny, Lula Rosso, Federico E Turkheimer, Nidal M Albarghach, Jean-Philippe Metges, Olivier Pradier, Dimitris Visvikis.   

Abstract

UNLABELLED: The objective of this study was to establish the repeatability and reproducibility limits of several volume-related PET image-derived indices-namely tumor volume (TV), mean standardized uptake value, total glycolytic volume (TGV), and total proliferative volume (TPV)-relative to those of maximum standardized uptake value (SUV(max)), commonly used in clinical practice.
METHODS: Fixed and adaptive thresholding, fuzzy C-means, and fuzzy locally adaptive Bayesian methodology were considered for TV delineation. Double-baseline (18)F-FDG (17 lesions, 14 esophageal cancer patients) and 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT) (12 lesions, 9 breast cancer patients) PET scans, acquired at a mean interval of 4 d and before any treatment, were used for reproducibility evaluation. The repeatability of each method was evaluated for the same datasets and compared with manual delineation.
RESULTS: A negligible variability of less than 5% was measured for all segmentation approaches in comparison to manual delineation (5%-35%). SUV(max) reproducibility levels were similar to others previously reported, with a mean percentage difference of 1.8% +/- 16.7% and -0.9% +/- 14.9% for the (18)F-FDG and (18)F-FLT lesions, respectively. The best TV, TGV, and TPV reproducibility limits ranged from -21% to 31% and -30% to 37% for (18)F-FDG and (18)F-FLT images, respectively, whereas the worst reproducibility limits ranged from -90% to 73% and -68% to 52%, respectively.
CONCLUSION: The reproducibility of estimating TV, mean standardized uptake value, and derived TGV and TPV was found to vary among segmentation algorithms. Some differences between (18)F-FDG and (18)F-FLT scans were observed, mainly because of differences in overall image quality. The smaller reproducibility limits for volume-derived image indices were similar to those for SUV(max), suggesting that the use of appropriate delineation tools should allow the determination of tumor functional volumes in PET images in a repeatable and reproducible fashion.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20720054     DOI: 10.2967/jnumed.110.078501

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  56 in total

1.  Impact of partial-volume effect correction on the predictive and prognostic value of baseline 18F-FDG PET images in esophageal cancer.

Authors:  Mathieu Hatt; Adrien Le Pogam; Dimitris Visvikis; Olivier Pradier; Catherine Cheze Le Rest
Journal:  J Nucl Med       Date:  2012-01       Impact factor: 10.057

Review 2.  Computerized PET/CT image analysis in the evaluation of tumour response to therapy.

Authors:  W Lu; J Wang; H H Zhang
Journal:  Br J Radiol       Date:  2015-02-27       Impact factor: 3.039

3.  Optimising delineation accuracy of tumours in PET for radiotherapy planning using blind deconvolution.

Authors:  A Guvenis; A Koc
Journal:  Radiat Prot Dosimetry       Date:  2015-04-01       Impact factor: 0.972

4.  The potential of 223Ra and 18F-fluoride imaging to predict bone lesion response to treatment with 223Ra-dichloride in castration-resistant prostate cancer.

Authors:  Iain Murray; Sarah J Chittenden; Ana M Denis-Bacelar; Cecilia Hindorf; Christopher C Parker; Sue Chua; Glenn D Flux
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06-13       Impact factor: 9.236

5.  Repeatability of 18F-FDG PET/CT in Advanced Non-Small Cell Lung Cancer: Prospective Assessment in 2 Multicenter Trials.

Authors:  Wolfgang A Weber; Constantine A Gatsonis; P David Mozley; Lucy G Hanna; Anthony F Shields; Denise R Aberle; Ramaswamy Govindan; Drew A Torigian; Joel S Karp; Jian Q Michael Yu; Rathan M Subramaniam; Robert A Halvorsen; Barry A Siegel
Journal:  J Nucl Med       Date:  2015-04-23       Impact factor: 10.057

Review 6.  Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations.

Authors:  Catherine S Diefenbach; Joseph M Connors; Jonathan W Friedberg; John P Leonard; Brad S Kahl; Richard F Little; Lawrence Baizer; Andrew M Evens; Richard T Hoppe; Kara M Kelly; Daniel O Persky; Anas Younes; Lale Kostakaglu; Nancy L Bartlett
Journal:  J Natl Cancer Inst       Date:  2016-12-31       Impact factor: 13.506

7.  Reproducibility and Repeatability of Semiquantitative 18F-Fluorodihydrotestosterone Uptake Metrics in Castration-Resistant Prostate Cancer Metastases: A Prospective Multicenter Study.

Authors:  Hebert Alberto Vargas; Gem M Kramer; Andrew M Scott; Andrew Weickhardt; Andreas A Meier; Nicole Parada; Bradley J Beattie; John L Humm; Kevin D Staton; Pat B Zanzonico; Serge K Lyashchenko; Jason S Lewis; Maqsood Yaqub; Ramon E Sosa; Alfons J van den Eertwegh; Ian D Davis; Uwe Ackermann; Kunthi Pathmaraj; Robert C Schuit; Albert D Windhorst; Sue Chua; Wolfgang A Weber; Steven M Larson; Howard I Scher; Adriaan A Lammertsma; Otto S Hoekstra; Michael J Morris
Journal:  J Nucl Med       Date:  2018-04-06       Impact factor: 10.057

8.  PET imaging for prediction of response to therapy and outcome in oesophageal carcinoma.

Authors:  Sue Chua; John Dickson; Ashley M Groves
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-09       Impact factor: 9.236

Review 9.  Importance of quantification for the analysis of PET data in oncology: review of current methods and trends for the future.

Authors:  Giampaolo Tomasi; Federico Turkheimer; Eric Aboagye
Journal:  Mol Imaging Biol       Date:  2012-04       Impact factor: 3.488

10.  A Virtual Clinical Trial of FDG-PET Imaging of Breast Cancer: Effect of Variability on Response Assessment.

Authors:  Robert L Harrison; Brian F Elston; Robert K Doot; Thomas K Lewellen; David A Mankoff; Paul E Kinahan
Journal:  Transl Oncol       Date:  2014-02-01       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.